IntroductionA progressive reduction in CD4 ϩ T-helper lymphocytes is the main feature of HIV infection and leads to a depression in adaptive immunity. 1 Innate immunity is also important in the host response to HIV infection and can be impaired during the course of this infection. Dendritic cells (DCs) can promote HIV transmission, [2][3][4][5] and DC function 6 and number 7 decline with HIV infection. The effector functions of monocytes and macrophages, including phagocytosis and intracellular oxidative responses, can be found decreased in HIV-infected subjects 8,9 and in cultured cells in the presence of HIV. [10][11][12][13] Superoxide production by neutrophils 14 as well as natural killer cell function as measured by the lymphokineactivated killer activity and responsiveness to interferon-␣ (IFN-␣) 15,16 have been shown to be defective in HIV-infected subjects.An important part of the innate defense against virus is the production of the type I IFNs, IFN-␣, and IFN-␤. 17 IFN-␣/␤ not only directly inhibit HIV replication, 18-20 but also have important adjuvant effects on a variety of immune cell types, such as monocytes, natural killer cells, 21 and T cells. [22][23][24][25][26] The in vitro type I IFN production by total peripheral blood mononuclear cells (PBMCs) was shown to be impaired during the course of HIV infection, and this impairment was associated with the occurrence of opportunistic infections. 27,28 CD4 ϩ CD11c Ϫ lineage marker Ϫ type 2 DC precursors (pre-DC2) were recently shown to be the natural IFN-␣/␤-producing cells in human blood. 29,30 IPCs produce up to 1000 times more IFN-␣ than any other blood cell type in response to viral stimulation. 29 Whether this impairment of IFN-␣/␤ production in HIV-infected individuals is due to a functional defect or to a reduction in number of IPCs is not known.In this study, we show that blood IPCs are severely decreased in AIDS patients but increased in asymptomatic long-term survivors (LTSs). The drop in IPC number and a decrease in their induced IFN production are associated with the presence of opportunistic infections and active Kaposi sarcoma. Our findings bring a new insight into the physiopathology of HIV infection and identify the IPC count as a new parameter to monitor the status of the immune system of HIV-infected subjects. Patients, materials, and methods HIV-infected subjectsFifty-four HIV-infected subjects were recruited from 3 centers: the University of California at San Francisco (UCSF), the San Francisco General Hospital, and the Hospices Civils de Lyon, France. This study was approved by the Committee for Human Research, UCSF. Subjects were enrolled consecutively, and the only inclusion criterion was a confirmed HIVpositive serology and a written informed consent. The following conditions, which can nonspecifically affect blood cell counts, were used as exclusion criteria: previous cytotoxic chemotherapy, splenectomy, hypersplenism, and blood transfusion within the past 4 weeks. After inclusion, a full medical history was taken and physic...

). Blockage of NS3 protease activity therefore is expected to inhibit HCV replication by both direct suppression of viral protein production as well as by restoring host responsiveness to IFN. Using structure-assisted design, a ketoamide inhibitor, SCH 503034, was generated which demonstrated potent (overall inhibition constant, 14 nM) time-dependent inhibition of the NS3 protease in cell-free enzyme assays as well as robust in vitro activity in the HCV replicon system, as monitored by immunofluorescence and real-time PCR analysis. Continuous exposure of repliconbearing cell lines to six times the 90% effective concentration of SCH 503034 for 15 days resulted in a greater than 4-log reduction in replicon RNA. The combination of SCH 503034 with IFN was more effective in suppressing replicon synthesis than either compound alone, supporting the suggestion of Foy and coworkers that combinations of IFN with protease inhibitors would lead to enhanced therapeutic efficacy.

The temporal gene expression profile during the entire process of apoptosis and cell cycle progression in response to p53 in human ovarian cancer cells was explored with cDNA microarrays representing 33 615 individual human genes. A total of 1501 genes (4.4%) were found to respond to p53 (approximately 80% of these were repressed by p53) using 2.5-fold change as a cutoff. It was anticipated that most of p53 responsive genes resulted from the secondary effect of p53 expression at late stage of apoptosis. To delineate potential p53 direct and indirect target genes during the process of apoptosis and cell cycle progression, microarray data were combined with global p53 DNA-binding site analysis. Here we showed that 361 out of 1501 p53 responsive genes contained p53 consensus DNA-binding sequence(s) in their regulatory region, approximately 80% of which were repressed by p53. This is the first time that a large number of p53-repressed genes have been identified to contain p53 consensus DNAbinding sequence(s) in their regulatory region. Hierarchical cluster analysis of these genes revealed distinct temporal expression patterns of transcriptional activation and repression by p53. More genes were activated at early time points, while more repressed genes were found after the onset of apoptosis. A small-scale quantitative chromatin immunoprecipitation analysis indicated that in vivo p53-DNA interaction was detected in eight out of 10 genes, most of which were repressed by p53 at the early onset of apoptosis, suggesting that a portion of p53 target genes in the human genome could be negatively regulated by p53 via sequence-specific DNA binding. The approaches and genes described here should aid the understanding of global gene regulatory network of p53.

No abstract

Publicly available genetic sequence data were searched for human sequences that potentially represent protein kinases, important players in virtually every signaling pathway. After removal of duplicates, splice variants and pseudogenes, this search yielded 510 sequences with recognizable similarity to eukaryotic protein kinases.

Anacetrapib is a novel cholesteryl-ester transfer protein (CETP) inhibitor in late-stage clinical development, shown in preceding clinical trials to have residual pharmacological activity after prolonged washout after chronic dosing. Preclinical findings suggest that white adipose tissue is a potential depot and that accumulation into adipose tissue governs the long-term kinetics of anacetrapib in mice. A phase I study performed to test this hypothesis in humans revealed that plasma exposure was correlated with fat content in food administered with the drug. Plasma concentrations of anacetrapib seemed to reach plateau faster than adipose concentrations. Anacetrapib continued to accumulate in adipose during the treatment period despite apparent plateau in plasma with only minimal decline in adipose levels up to 1 year postdose. Because of its high lipophilicity, anacetrapib partitions into adipose tissue, this likely forms a drug reservoir that, in turn, contributes to the long residence time of the drug in plasma.

The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibits a long terminal half-life (t ½ ) in humans; however, the dispositional mechanisms that lead to this long t ½ are still being elucidated. As it is hypothesized that disposition into adipose tissue and binding to CETP might play a role, we sought to delineate the relative importance of these factors using a preclinical animal model. A multiple-dose pharmacokinetic study was conducted in C57BL6 wild-type (WT) lean, WT diet-induced obese (DIO), natural flanking region (NFR) CETP-transgenic lean, and NFR-DIO mice. Mice were dosed orally with 10 mg/kg anacetrapib daily for 42 days. Drug concentrations in blood, brown and white adipose tissue, liver, and brain were measured up to 35 weeks postdose. During dosing, a 3-to 9-fold accumulation in 72-hour postdose blood concentrations of anacetrapib was observed. Drug concentrations in white adipose tissue accumulated ∼20-to 40-fold, whereas 10-to 17-fold accumulation occurred in brown adipose and approximately 4-fold in liver. Brain levels were very low (<0.1 mM), and a trend of accumulation was not seen. The presence of CETP as well as adiposity seems to play a role in determining the blood concentrations of anacetrapib. The highest blood concentrations were observed in NFR DIO mice, whereas the lowest concentrations were seen in WT lean mice. In adipose and liver tissue, higher concentrations were seen in DIO mice, irrespective of the presence of CETP. This finding suggests that white adipose tissue serves as a potential depot and that disposition into adipose tissue governs the long-term kinetics of anacetrapib in vivo.

No abstract